Media stories about Aratana Therapeutics (NASDAQ:PETX) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.6253502777895 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Shares of Aratana Therapeutics (NASDAQ PETX) opened at 5.71 on Friday. The firm’s market capitalization is $245.54 million. The firm’s 50 day moving average is $6.19 and its 200-day moving average is $6.28. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $8.92.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. Aratana Therapeutics’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 earnings per share. On average, analysts expect that Aratana Therapeutics will post ($1.09) EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, July 4th. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Jefferies Group LLC set a $8.00 price objective on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Lake Street Capital cut their price objective on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Aratana Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.25.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-stock-price.html.
In related news, insider Ernst Heinen sold 10,000 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $6.25, for a total value of $62,500.00. Following the sale, the insider now owns 130,994 shares of the company’s stock, valued at approximately $818,712.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,000 shares of company stock worth $435,600. 5.20% of the stock is currently owned by company insiders.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.